Looking at China's chemical pharmaceutical industry, which pharmaceutical enterprise is more optimistic?

[editor's view of chinapharma.com] since 2018, China's consistency evaluation has been steadily promoted, and relevant opinions on medical insurance payment standards have been published one after another, and a reshuffle in the field of medicine is imminent In the subdivided industries, the competition pattern in the field of chemical generic drugs is good, but influenced by the policy of "purchasing with quantity", domestic chemical pharmaceutical enterprises are also impacted to some extent So, looking at the field, which pharmaceutical company is more optimistic? (looking at China's chemical pharmaceutical industry, which pharmaceutical enterprise is more favored? Photo source: Qilu Pharmaceutical Co., Ltd held the 2018 annual summit of China's chemical pharmaceutical industry in Nanjing on October 16 At the meeting, the 2018 China chemical pharmaceutical industry enterprise and product brand list was released and awarded Qilu Pharmaceutical Group won quite a lot, with a total of 23 awards Among them, Qilu Pharmaceutical Group won the honor of "top ten Chinese pharmaceutical industry enterprise groups in 2018", and its five subsidiaries were shortlisted in the list of "top 100 comprehensive strength of Chinese chemical pharmaceutical industry enterprises in 2018" In terms of products, Qilu pharmaceutical is currently engaged in more than 120 new drug research projects, of which more than 30 are innovative drug projects Since this year, Qilu pharmaceutical has had 7 new drugs approved and listed one after another, which shows that its R & D strength is strong In addition, in the next few years, Qilu Pharmaceutical Group is expected to have a number of innovative drugs into phase II-III clinical stage, bringing more benefits to patients Yuheng Pharmaceutical Co., Ltd on October 16, 2018, the 2018 China chemical pharmaceutical industry annual summit with the theme of "quality and integrity brand" was held in Nanjing At the meeting, Yuheng pharmaceutical won the title of 2018 top 100 industrial enterprises with comprehensive strength in China's chemical pharmaceutical industry 2018 is a challenging year for Yuheng Pharmaceutical Co., Ltd to actively respond to market and policy changes and promote the continuous transformation of the company On the one hand, the company has adjusted its sales channels, reduced the inventory of channel products, and increased its professional promotion; on the other hand, the company has made further distribution of biological drugs and chronic diseases, and concentrated resources to accelerate the distribution of biological drugs and chronic diseases, which has achieved initial results According to the third quarter report released by the company on October 25, From January to September 2018, the company achieved an operating revenue of 3.962 billion yuan, up 99.17% year-on-year; the chemical pharmaceutical industry has disclosed an average operating revenue growth rate of 36.19% for individual shares in the third quarter; the net profit attributable to shareholders of listed companies is 314 million yuan, up 9.4% year-on-year; the chemical pharmaceutical industry has disclosed an average net profit growth rate of 62.04% for individual shares in the third quarter The company said that the adverse effect of the "two vote system" policy on its product sales was gradually eliminated Beijing new pharmaceutical 2018 annual summit of China's chemical pharmaceutical industry, Beijing new pharmaceutical industry won many honors, such as 39 top 100 industrial enterprises with comprehensive strength in China's chemical pharmaceutical industry in 2018, and growth enterprise brand in China's chemical pharmaceutical industry in 2018 Risuvastatin calcium, a key product of Jingxin pharmaceutical, is a kind of lipid regulating drug, which has obvious effect on reducing total cholesterol, low-density lipoprotein cholesterol and triglyceride In February 2018, multiple product specifications of the product have passed the consistency evaluation of quality and efficacy of generic drugs In addition, several OTC products of Beijing new pharmaceutical industry, such as dingkundan, shenzhujing capsule, Kangfuxin Liquid, Bacillus licheniformis viable capsule, are also favored in the market According to the analysis of Sansheng pharmaceutical industry, the "4 + 7" volume procurement will inevitably have an impact on the domestic pharmaceutical pattern For investors, the future of the blue ocean is bound to run out of those pharmaceutical companies with innovative value Among them, Sansheng pharmaceutical is favored by the industry The main reason is that Sansheng pharmaceutical, as the benchmark of domestic innovative pharmaceutical enterprises, has experienced a long time of tempering, relatively stable operation, strong R & D technology background and advantages, certain basis in sales channels, and obvious resource advantages At present, three core product groups have been formed, all of which have maintained a dominant position in the market and accelerated their growth At the same time, the company has a rich second-line product group, covering five potential diseases such as kidney disease, tumor, autoimmune, dermatology and diabetes According to the industry's comprehensive three quarter report, as of June 30, 2018, Sansheng pharmaceutical's operating revenue in the first half of the year was 2.174 billion yuan (the same below), an increase of 27.4% year-on-year, and its gross profit was 1.746 billion yuan, an increase of 19.9% year-on-year It can be seen that the pharmaceutical enterprise has strong profitability, which will also boost the company's product research and development, and form a strong pharmaceutical giant In addition, with the promotion of the volume purchase, the stock price of Sansheng pharmaceutical fluctuated in the short term, but the industry believes that investors do not need to worry too much Therefore, both short-term and long-term belt mining policies will not have a great impact on Sansheng.